RNTXRein Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Rein Therapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RNTXThis | $63M#4 | — | 5.5x#3 | — | — | 20.7%#1 | — | -430.5%#4 | — | — | -35.7%#3 | — |
| RLMD | $527M#1 | — | 2.4x#2 | 102661.1x#2 | -35.4%#2 | — | -1152275.3%#2 | 0.0%#1 | — | — | 684.3%#1 | — |
| RMTI | $275M#2 | — | 7.7x#4 | 4.0x#1 | -31.8%#1 | -1007.1%#2 | -6.8%#1 | -14.8%#3 | -13.3%#1 | 3#1 | -24.6%#2 | — |
| RNA | $194M#3 | — | 0.8x#1 | — | — | — | — | 0.0%#1 | — | — | -69.1%#4 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-08-01.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice